Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels

Current disease-modifying therapies for Huntington disease (HD) focus on lowering mutant HTT (huntingtin; mHTT) levels, and the immunosuppressant drug rapamycin is an intriguing therapeutic for aging and neurological disorders. Rapamycin interacts with FKBP1A/FKBP12 and FKBP5/FKBP51, inhibiting the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailus, Barbara J., Scheeler, Stephen M., Simons, Jesse, Sanchez, Maria A., Tshilenge, Kizito-Tshitoko, Creus-Muncunill, Jordi, Naphade, Swati, Lopez-Ramirez, Alejandro, Zhang, Ningzhe, Lakshika Madushani, Kuruwitage, Moroz, Stanislav, Loureiro, Ashley, Schreiber, Katherine H., Hausch, Felix, Kennedy, Brian K., Ehrlich, Michelle E., Ellerby, Lisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726715/
https://www.ncbi.nlm.nih.gov/pubmed/34024231
http://dx.doi.org/10.1080/15548627.2021.1904489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726715/
https://www.ncbi.nlm.nih.gov/pubmed/34024231
http://dx.doi.org/10.1080/15548627.2021.1904489

Ejemplares similares